Key Highlights

  • Adherium reported RPM subscription Revenue of $539,000 for the September quarter, up from $479,000 in the June quarter.
  • Cash was just $120,000 at 30 September after a net operating outflow of $3.5 million, with an estimated 0.03 quarters of funding.
  • Trudell agreed to combine several earlier loans into a single $4.67 million term Loan due 31 August 2027.
  • A new Barvest Facility carries 12% interest and is repayable on 26 October 2027, adding to related-party debt.

Adherium (ASX:ADR) is growing Recurring Revenue from its Hailie inhaler sensor platform in the United States, but its Balance Sheet depends heavily on loans from parties related to its major shareholder, Trudell Medical. According to its September quarter (Q1 FY27) Appendix 4C, released on 30 October 2026, the company held just $120,000 in cash at quarter end after a net operating outflow of $3.5 million. That gave an estimated 0.03 quarters of funding.

Since then it has drawn new money. On 30 October Adherium announced an additional $750,000 Unsecured Loan facility from Barvest Ventures, a Trudell-related investor, on top of a $700,000 Barvest facility received on 7 October. The company also received a $257,917 milestone payment from AstraZeneca on 9 October.

What Adherium does

Adherium develops the Hailie sensor, which has FDA clearance and attaches to common inhalers to record use and technique, together with the Hailie Care clinical service. Its commercial focus is the US, where remote patient monitoring (RPM) is reimbursed under established billing codes and the platform can be distributed through respiratory practices. The company notes that Hailie Care is not approved for commercial Supply in Australia.

Revenue is growing from a small base

The Quarterly Report showed RPM subscription revenue of $539,000, up from $479,000 in the June quarter, and customer cash receipts of $544,000. Shipments of 1,033 devices and 900 activations took the cumulative totals to 6,392 shipments and 4,732 activations. Billable revenue is recognised when patients are activated, so shipments do not translate directly into income.

On 26 October Adherium announced a Partnership with Florida Lung, Asthma & Sleep Specialists, an independent pulmonary practice in the Orlando area. The practice will implement Hailie for remote therapeutic monitoring of asthma and COPD patients. No contract value was disclosed. There have also been Leadership changes: John Perry became interim chief executive in July, and Brad Wilson was appointed chief financial officer on 12 October.

The Debt position

Operating costs remain far above receipts. In the quarter, staff costs were $2.09 million and administration and corporate costs were $1.47 million. Funding came mainly from $2.32 million of borrowings. The Appendix 4C says Trudell agreed to combine several earlier unsecured loans with accrued interest into a single $4.67 million term loan due 31 August 2027, all of which was drawn at quarter end. The new Barvest facility carries 12% interest, capitalised monthly, and is repayable on 26 October 2027.

In its item 8 commentary, Adherium said it is confident it will continue to raise sufficient funds and cited the October loans and milestone receipt. This suggests the company remains reliant on its major Shareholder group in the near term. Those post-quarter inflows of about $1.7 million are small relative to the quarterly burn.

Risks and upcoming milestones

Digital health and RPM providers in the US face reimbursement risk, competition and the cost of building clinical teams. The specific risks for Adherium are its funding gap, rising related-party debt with maturities in 2027, and future Equity dilution. The Annual General Meeting will be held virtually on Monday 30 November 2026 at 9.30am (AEDT). Resolutions include approval of an additional 10% Placement capacity under Listing Rule 7.1A and an issue of shares to a consultant in lieu of fees.